SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3
Coates LC, Mcgonagle D, Schett G, Mease PJ, Quebe-Fehling E, Asquith DL, Rasouliyan L, Mpofu S, Gaillez C (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 98
Pages Range: 19-19
DOI: 10.1093/rheumatology/kez107.071
Authors with CRIS profile
Involved external institutions
University of Oxford
United Kingdom (GB)
University of Leeds
United Kingdom (GB)
Novartis AG
Switzerland (CH)
Swedish Medical Center
United States (USA) (US)
RTI Health Solutions
United States (USA) (US)
Novartis UK
United Kingdom (GB)
United Kingdom (GB)
University of Leeds
United Kingdom (GB)
Novartis AG
Switzerland (CH)
Swedish Medical Center
United States (USA) (US)
RTI Health Solutions
United States (USA) (US)
Novartis UK
United Kingdom (GB)
How to cite
APA:
Coates, L.C., Mcgonagle, D., Schett, G., Mease, P.J., Quebe-Fehling, E., Asquith, D.L.,... Gaillez, C. (2018). SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3. (pp. 19-19).
MLA:
Coates, Laura C., et al. "SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3." 2018. 19-19.
BibTeX: Download